BRUSSELS (Reuters) - Belgian biotech group Galapagos NV on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/RZTPNL5uKj8/story01.htm
Read More
No comments:
Post a Comment